efficacy and security of ocrelizumab in patients with remittent recurrent multiple sclerosis (rrms) in a tertiary care hospital multiple sclerosis unit.

Authors
Category Primary study
Conference40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, ECTRIMS 2024
Year 2024
This article has no abstract
Epistemonikos ID: 1f8ac265595849b74ff9e1f95bc0b7db3468407a
First added on: Mar 31, 2026